INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 443m ago
HOUSE PTR42m ago
SEC 13F42m ago
ROBINHOOD CHAIN42m ago
Public company

Travere Therapeutics, Inc.

TVTXCIK 0001438533

EDGAR filingsOpen in network
Price$49.60
1 year+47.1%
Disclosed transactions60
Buys / sells0 / 25
Max Insider Score35
Connections with evidence11

TVTX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
200.0K sh
Oct 15, 2026Oct 19, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Holds over 5% ofevidence
    FMR LLC6.1% of class · Schedule 13G · Nov 4, 2026
  • ← Lobbied forevidence
    LMH STRATEGIC SOLUTIONSLDA Q1 2026 first quarter · Pharmacy · Aug 26, 2026
  • ← Lobbied forevidence
    ALSTON & BIRD LLPLDA Q2 2026 second quarter · Health issues, Medicare/Medicaid, Pharmacy, MED, Taxation · Aug 26, 2026
  • ← Lobbied forevidence
traded Oct 15, 2026
+4d
SEC FORM 4

Evidence

11
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$4.31M
78.4K sh
Oct 15, 2026Oct 19, 2026
traded Oct 15, 2026
+4dSEC FORM 4

Evidence

11
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$2.02M
37.3K sh
Oct 15, 2026Oct 19, 2026
traded Oct 15, 2026
+4dSEC FORM 4

Evidence

11
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$6.78M
128.1K sh
Oct 15, 2026Oct 19, 2026
traded Oct 15, 2026
+4dSEC FORM 4

Evidence

9
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$1.79M
200.0K sh
Oct 15, 2026Oct 19, 2026
traded Oct 15, 2026
+4dSEC FORM 4

Evidence

5
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$1.18M
43.7K sh
Oct 15, 2026Oct 19, 2026
traded Oct 15, 2026
+4dSEC FORM 4

Evidence

0
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
43.7K sh
Oct 15, 2026Oct 19, 2026
traded Oct 15, 2026
+4dSEC FORM 4

Evidence

21
IJ
Inrig JulaEVP, Head of R&D & CMO
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.08M
17.3K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

11
IJ
Inrig JulaEVP, Head of R&D & CMO
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$102K
1,600 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$28K
1,250 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$33K
1,625 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

21
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$266K
4,275 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

14
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$50K
800 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

11
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$19K
300 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,500 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

11
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$121K
1,900 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

21
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.70M
27.5K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

21
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.30M
20.7K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

21
IJ
Inrig JulaEVP, Head of R&D & CMO
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.57M
25.4K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

2
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$69K
2,500 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

4
IJ
Inrig JulaEVP, Head of R&D & CMO
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
32.4K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

8
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
400 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

6
IJ
Inrig JulaEVP, Head of R&D & CMO
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$289K
32.4K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

8
IJ
Inrig JulaEVP, Head of R&D & CMO
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
400 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

0
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,625 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

7
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
1,250 sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
20.0K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

2
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$349K
20.0K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

5
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Gift
G—
468 sh
Jun 22, 2026Jun 22, 2026
traded Jun 22, 2026
+0dSEC FORM 4

Evidence

0
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award · 10b5-1 plan
A—
45.0K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

16
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$102K
2,181 sh
May 5, 2026May 6, 2026
traded May 5, 2026
+1dSEC FORM 4

Evidence

13
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$14K
310 sh
May 6, 2026May 6, 2026
traded May 6, 2026
+0dSEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award · 10b5-1 plan
A—
8,500 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

0
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

2
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$448K
20.0K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

23
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$900K
20.0K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

16
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$101K
2,174 sh
May 5, 2026May 6, 2026
traded May 5, 2026
+1dSEC FORM 4

Evidence

13
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$14K
311 sh
May 6, 2026May 6, 2026
traded May 6, 2026
+0dSEC FORM 4

Evidence

4
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
20.0K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

0
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award · 10b5-1 plan
A—
8,500 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

0
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Grant or award
A—
8,500 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

5
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

0
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
22.5K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

22
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$989K
22.5K sh
May 6, 2026May 6, 2026
traded May 6, 2026
+0dSEC FORM 4

Evidence

0
DM
Dube Eric MDirector, CHIEF EXECUTIVE OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
22.5K sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

35
HP
Heerma PeterCHIEF COMMERCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale
SELL$101K
2,174 sh
May 5, 2026May 6, 2026
traded May 5, 2026
+1dSEC FORM 4

Evidence

0
IJ
Inrig JulaCHIEF MEDICAL OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,250 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

26
RE
Rote William E.Chief Research Officer
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$356K
9,100 sh
Apr 22, 2026Apr 23, 2026
traded Apr 22, 2026
+1dSEC FORM 4

Evidence

2
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$56K
6,250 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

7
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,500 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

7
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,500 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

2
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$56K
2,500 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

2
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$133K
6,500 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

7
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
6,250 sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

30
CS
Calvin SandraSVP, CHIEF ACCOUNTING OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$903K
22.0K sh
Apr 14, 2026Apr 16, 2026
traded Apr 14, 2026
+2dSEC FORM 4

Evidence

26
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$304K
7,239 sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

16
CR
Cline Christopher R.CHIEF FINANCIAL OFFICER
TVTXTravere Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$370
9 sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

THE HEALTH EQUITY STRATEGIES GROUP, LLC
LDA Q2 2026 second quarter · Health issues, MED, Medicare/Medicaid, Pharmacy · Aug 26, 2026
  • ← Insider ofevidence
    Cline Christopher R.CHIEF FINANCIAL OFFICER · Feb 5, 2026
  • ← Insider ofevidence
    Dube Eric MDirector, CHIEF EXECUTIVE OFFICER · Jan 27, 2026
  • ← Insider ofevidence
    Heerma PeterCHIEF COMMERCIAL OFFICER · Dec 29, 2025
  • ← Insider ofevidence
    Inrig JulaCHIEF MEDICAL OFFICER · Dec 29, 2025
  • ← Insider ofevidence
    Rote William E.Chief Research Officer · Dec 29, 2025
  • ← Insider ofevidence
    Calvin SandraSVP, CHIEF ACCOUNTING OFFICER · Nov 6, 2025

    • Lobbying

    $340K reported · de-duplicated
    2026 Q2 $140K in-house2026 Q1 $200K in-house
    • LMH STRATEGIC SOLUTIONS—2026 Q1 · posted Aug 26, 2026 ·
    • THE HEALTH EQUITY STRATEGIES GROUP, LLC$16K2026 Q2 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid, Pharmacy
    • ALSTON & BIRD LLP$70K2026 Q2 · posted Aug 26, 2026 · Health issues, Medicare/Medicaid, Pharmacy, MED, Taxation
    • ALSTON & BIRD LLP$80K2026 Q1 · posted Aug 26, 2026 · Pharmacy, Health issues, Medicare/Medicaid, MED, Taxation
    • In-house report$200K2026 Q1 · posted Aug 26, 2026 · Copyright/patent, Health issues, Pharmacy, MED, Medicare/Medicaid, Taxation
    • THE HEALTH EQUITY STRATEGIES GROUP, LLC$16K2026 Q1 · posted Aug 26, 2026 · Health issues, MED, Medicare/Medicaid, Pharmacy
    • In-house report$140K2026 Q2 · posted Aug 26, 2026 · Health issues, Pharmacy, MED, Medicare/Medicaid, Copyright/patent, Taxation
    • LMH STRATEGIC SOLUTIONS$30K2026 Q1 · posted Aug 26, 2026 · Pharmacy

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.

    Planned sales and 5% stakes

    Form 144, 13D and 13G
    • FMFMR LLCPassive holder · crossed on Sep 30, 2026 · 5.71M shares6.1% of class13G amendment · filed Nov 5, 2026